Xia Kailin, Huang Ninghao, Wang Yajun, Zhang Gan, Tang Lu, Zhang Linjing, Yao Minhao, Liu Zhonghua, Huang Tao, Fan Dongsheng
Department of Neurology, Peking University Third Hospital, Beijing, China.
Beijing Key Laboratory of Biomarker and Translational Research in Neurodegenerative Diseases, Beijing, China.
Neural Regen Res. 2025 Aug 13. doi: 10.4103/NRR.NRR-D-25-00266.
Growing evidence suggests that abnormal lipid metabolism occurs in amyotrophic lateral sclerosis, even in the presymptomatic stage, implying an etiologic link. However, the genetic mechanism underlying altered lipid levels in amyotrophic lateral sclerosis remains elusive. Therefore, in this study, we performed genetic correlation analysis, a cross-trait meta-analysis, tissue-specific enrichment analysis, and bidirectional two-sample Mendelian randomization analysis of European population to explore whether there is a genetic and causal relationship between lipids and amyotrophic lateral sclerosis. The effect of lipid-lowering drugs on amyotrophic lateral sclerosis was also evaluated using a drug target Mendelian randomization approach. The results showed a positive genetic correlation between amyotrophic lateral sclerosis and both high-density lipoprotein cholesterol and apolipoprotein A1 and identified 71 independent shared loci between amyotrophic lateral sclerosis and high-density lipoprotein cholesterol, as well as 55 independent shared loci between amyotrophic lateral sclerosis and apolipoprotein A1. These shared loci were enriched in the lipid metabolic pathway and the alcohol metabolic pathway. Further Mendelian randomization analysis targeting lipid-lowering drugs showed that single nucleotide polymorphisms within the ACLY and PCSK9 genes had a protective effect against amyotrophic lateral sclerosis risk by decreasing low-density lipoprotein cholesterol. The combination of ACLY and PCSK9 inhibitors has a greater protective effect on amyotrophic lateral sclerosis risk than that of PCSK9 inhibitors alone. In summary, there is a common genetic structure between lipids and amyotrophic lateral sclerosis. Mendelian randomization analysis supports an association between elevated blood lipids and the risk of developing amyotrophic lateral sclerosis, and the use of ACLY or PCSK9 inhibitors may improve disease prognosis.
越来越多的证据表明,肌萎缩侧索硬化症(ALS)患者存在脂质代谢异常,即使在症状前期也是如此,这暗示了两者之间的病因联系。然而,ALS患者脂质水平改变的遗传机制仍不清楚。因此,在本研究中,我们对欧洲人群进行了遗传相关性分析、跨性状荟萃分析、组织特异性富集分析和双向两样本孟德尔随机化分析,以探讨脂质与ALS之间是否存在遗传和因果关系。我们还使用药物靶点孟德尔随机化方法评估了降脂药物对ALS的影响。结果显示,ALS与高密度脂蛋白胆固醇和载脂蛋白A1均呈正遗传相关性,并确定了71个ALS与高密度脂蛋白胆固醇之间的独立共享位点,以及55个ALS与载脂蛋白A1之间的独立共享位点。这些共享位点在脂质代谢途径和酒精代谢途径中富集。针对降脂药物的进一步孟德尔随机化分析表明,ACLY和PCSK9基因内的单核苷酸多态性通过降低低密度脂蛋白胆固醇对ALS风险具有保护作用。ACLY和PCSK9抑制剂联合使用对ALS风险的保护作用比单独使用PCSK9抑制剂更大。总之,脂质与ALS之间存在共同的遗传结构。孟德尔随机化分析支持血脂升高与发生ALS风险之间的关联,使用ACLY或PCSK9抑制剂可能改善疾病预后。